# Adjuvant Melatonin for Uveal Melanoma

> **NCT05502900** · PHASE3 · RECRUITING · sponsor: **Gustav Stalhammar** · enrollment: 100 (estimated)

## Conditions studied

- Uveal Melanoma
- Uveal Melanoma, Posterior, Medium/Large Size
- Eye Cancer, Intraocular Melanoma

## Interventions

- **DRUG:** Melatonin

## Key facts

- **NCT ID:** NCT05502900
- **Lead sponsor:** Gustav Stalhammar
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-02
- **Primary completion:** 2031-01-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05502900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05502900, "Adjuvant Melatonin for Uveal Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05502900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*